Safety and tolerability of transdermal cannabidiol gel in children with developmental and epileptic encephalopathies

9/3/21–In this nonrandomized controlled trial, CBD transdermal gel was well tolerated over 6.5 months of treatment, with 60% of patients experiencing a treatment-related adverse event, 96% of which were mild or moderate. A 43.5% reduction in seizure frequency was observed in focal impaired awareness seizures and tonic-clonic seizures. These results suggest that CBD transdermal gel is well tolerated in children with developmental and epileptic encephalopathies and may be associated with a reduction in epileptic seizures. Read